New Rhein Healthcare

Corsair Pharma is focused on developing innovative drug solutions to enhance the therapeutic profiles of existing medications, with an emphasis on improving treatment options for patients. The company is specifically advancing a novel prodrug of treprostinil, which is engineered to permeate the skin, enter the bloodstream, and convert swiftly to active treprostinil in the liver. This unique approach aims to facilitate effective and rapid titration of parenteral delivery, allowing healthcare professionals to treat patients with pulmonary arterial hypertension (PAH) through a once-daily transdermal patch. By prioritizing patient outcomes, Corsair Pharma is positioned to deliver superior therapeutic solutions in the pharmaceutical landscape.

Theranica is a medical device company specializing in the development of electroceuticals that utilize neuromodulation therapy combined with advanced wireless technology. The company has created a proprietary wearable solution, specifically a non-invasive 'smart' patch, designed to address various medical conditions, with a primary focus on migraine headaches. This innovative product is controlled via a smartphone app, allowing for personalized and portable treatment options. The patch features a unique 'smart' chip that delivers electrical pulses to modulate the sensory nerves beneath the skin, offering patients an effective means of managing acute migraines. Theranica's solutions aim to provide affordable care and enhance the quality of life for individuals suffering from neurological pain.

Butterfly Medical Ltd is a medical-device company founded in 2014 and based in Yokne'am, Israel. It specializes in the development of an implantable device aimed at treating Benign Prostatic Hyperplasia (BPH), a condition commonly referred to as enlarged prostate. The company's innovative device provides a fast, simple, and minimally invasive alternative to conventional BPH treatments, including medications and surgery. It can be implanted in under ten minutes in an office setting using local anesthesia, without the need for surgical incisions or removal of prostate tissue. This approach not only minimizes side effects but also eliminates the requirement for hospitalization or general anesthesia. Initial clinical trials have shown promising results, with effective outcomes in opening blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies in leading medical centers across Europe to validate its device's efficacy and safety.

American Injectables is a manufacturer specializing in sterile injectable drugs, with a state-of-the-art facility dedicated to producing ready-to-use prefilled syringes and vials. The company aims to address current drug shortages by developing products that enhance efficiency for healthcare professionals and pharmacy departments. Its offerings are designed to minimize the resources required for the preparation and administration of common medications in hospitals, outpatient centers, and clinics. By providing pharmaceutical companies with access to convenient prefilled solutions, American Injectables contributes to improved medication delivery in various healthcare settings.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for the treatment of peripheral nerve injuries (PNI). Founded in 2016 and headquartered in Louisville, Colorado, with additional offices in Philadelphia and Lafayette, the company aims to enhance recovery outcomes for patients undergoing surgical interventions for acute nerve injuries. Its product portfolio includes AxoFuse, a nerve repair system that mitigates nerve degeneration and limb atrophy; AxoTrim, a surgical instrument designed for nerve preparation; AxoBond, which secures surgically repaired nerves during recovery; and NTX-001, a drug-device product intended for use in surgical nerve repairs and reconstructive procedures. Neuraptive Therapeutics commercializes technology developed at the University of Texas, emphasizing the advancement of microsurgical techniques in the treatment of peripheral nerves.

Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for the treatment of peripheral nerve injuries (PNI). Founded in 2016 and headquartered in Louisville, Colorado, with additional offices in Philadelphia and Lafayette, the company aims to enhance recovery outcomes for patients undergoing surgical interventions for acute nerve injuries. Its product portfolio includes AxoFuse, a nerve repair system that mitigates nerve degeneration and limb atrophy; AxoTrim, a surgical instrument designed for nerve preparation; AxoBond, which secures surgically repaired nerves during recovery; and NTX-001, a drug-device product intended for use in surgical nerve repairs and reconstructive procedures. Neuraptive Therapeutics commercializes technology developed at the University of Texas, emphasizing the advancement of microsurgical techniques in the treatment of peripheral nerves.

Softhale is a medical device company specializing in the development of Soft Mist Inhalation (SMI) devices designed for the effective delivery of pharmaceutical drugs to the lungs. The company's innovative devices utilize a proprietary set of technical configurations to spray a propellant-free liquid formulation efficiently. This design allows the medication to navigate the natural curve of the throat, giving patients the opportunity to inhale the treatment deeply into their lungs. By enhancing the delivery of inhalable therapeutics, Softhale aims to improve respiratory treatments and provide relief for individuals suffering from chronic respiratory conditions.

Chase Pharmaceuticals Corporation is a specialty pharmaceutical company established in 2007 and headquartered in Washington, D.C. The company is dedicated to developing innovative medications aimed at treating Alzheimer's disease and related neurodegenerative disorders. Its primary product, CPC-252, is a transdermal formulation designed for managing the symptoms of Alzheimer's and Parkinsonism dementia. Chase Pharmaceuticals focuses on identifying and advancing promising treatments for central nervous system diseases, with a goal of addressing the significant unmet medical need in neuropsychiatry, particularly with Alzheimer’s disease, which is recognized as a major public health challenge. The company operates by selecting and developing product candidates that can be licensed to commercial partners, thus contributing to its strategic aim of improving the quality of life for those affected by cognitive decline. With an increasing global population affected by Alzheimer's and escalating healthcare costs, Chase Pharmaceuticals is positioned to play a crucial role in the development of more effective therapies for this condition.

Biocartis SA, established in 2007 and headquartered in Lausanne, Switzerland, is a molecular diagnostics company specializing in developing diagnostic technology platforms for multiplexed detection of bio-analytes such as proteins, nucleic acids, and small molecules. The company focuses on integrated molecular and immunodiagnostics using its proprietary micro-technology platform, offering products like the Idylla system for oncology and infectious disease segments. These products aid in early detection, staging, treatment selection, and monitoring of diseases by analyzing bio-molecules associated with risk factors. Biocartis generates revenue primarily through product sales.